Dalrada Health

VIA Test: Immediate Diagnosis for a World Without Cervical Cancer
The first documented case of human cancer dates back to 1500 BC. More recently, when it was first discovered and identified in 1834, Cervical cancer was thought to be a sexually transmitted disease. Years of research have concluded that’s not always the case and occurrences depend on a number of factors. Today, every two minutes, a woman dies of cervical cancer. It’s currently ranked the highest cause of death from cancer in 36 countries, and unfortunately, it holds the distinction of having the fourth-highest mortality rate among women around the world.

Early detection and treatment of Cervical cancer can save countless lives. Drawing on that fact, a global pact has been enacted to eliminate cervical cancer by the year 2030 using evidence-based prevention techniques, such as screening as a preventive measure.

CERVICAL CANCER – A GLOBAL PERSPECTIVE

In many developed countries, the Cervical cancer annual incidence and mortality rate have decreased by 50-70% with simple population-based screening.

Yet on a global scale, 85% of annual deaths from Cervical cancer occur in low-to-middle income countries where access to preventative measures is often limited and the disease is not identified until symptoms appear in advanced stages.

Studies have indicated that visual inspection with acetic acid (VIA) screening – in the presence of good training and sustained quality assurance – can immediately detect Cervical cancer. VIA tests are helpful, particularly in countries with large low-to-medium income populations.

According to the SEER (Surveillance, Epidemiology, and End Results) database that analyzed U.S. cervical cancer diagnoses between 2010-2016, the survivability rate of “distant” advanced Cervical cancer (spread to nearby organs or distant parts of the body such as the lungs or bones) is 17%, whereas survivability of localized (early stage) disease is 92%, according to the American Cancer Society.

VIA TESTS RAPIDLY DETECT CERVICAL CANCER

Every day counts for patients and practitioners when identifying Cervical cancer, especially those with advanced cases. For years, the go-to Cervical cancer cytology-based screening test was the Pap smear (first discovered in 1923). However, after a healthcare provider collects a sample for laboratory analysis with this test, it can take weeks for an anxious woman to receive the results.

A timesaving alternative, proven in a clinical study, visual inspection with acetic acid (VIA), surpasses the effectiveness of the traditional Pap test. VIA is also used to validate other test results as a viable second opinion.

Of all the Cervical cancer screening tests used today, only visual inspection with acetic acid (VIA) provides immediate, actionable results.

Dalrada Health’s cerVIA™ cervical cancer screening test plays a vital role in immediate detection.


cerVIA TEST KIT™ BY DALRADA HEALTH

Dalrada Health believes that every life is precious.

Committed to reducing the burden of Cervical cancer worldwide, Dalrada Health dedicates support to research programs that help save lives, especially in high-risk countries like India. Long-term studies have been conducted around the world that ultimately show the effectiveness of the VIA-based screening approach. In India, for example, Cervical cancer mortality was reduced by 31% over 15 years among women screened with VIA.

Dalrada Health’s cerVIA™ screening kits ensure quality control for consistent validation processes. The single-use disposable cerVIA Test Kit™ is based on the World Health Organization’s recommended procedure for conducting a visual inspection with acetic acid (VIA). It contains all the necessary elements required for the test to be done by a healthcare professional in a primary healthcare setting.

The cerVIA Test Kit™ kit makes it easy for screening centers to manage multiple aspects such as ensuring consistency and quality of the kit’s components to confirming that all active ingredients are sourced from FDA or ISO-approved facilities. Ensuring that the validation process is consistent, each kit uses identical components. For additional information about Dalrada Health and the cerVIA Test Kit™, please visit  www.dalradahealth.com.

basic via kit
divider

DALRADA
LATEST NEWS

VIA Test: Immediate Diagnosis for a World Without Cervical Cancer
The first documented case of human cancer dates back to 1500 BC. More recently, when it was first discovered and identified in 1834, Cervical cancer was thought to be a sexually transmitted disease. Years of research have concluded that’s not always the case and occurrences depend on a number of factors. Today, every two minutes, a woman dies of cervical cancer. It’s currently ranked the highest cause of death from cancer in 36 countries, and unfortunately, it holds the distinction of having the fourth-highest mortality rate among women around the world.

Early detection and treatment of Cervical cancer can save countless lives. Drawing on that fact, a global pact has been enacted to eliminate cervical cancer by the year 2030 using evidence-based prevention techniques, such as screening as a preventive measure.

CERVICAL CANCER – A GLOBAL PERSPECTIVE

In many developed countries, the Cervical cancer annual incidence and mortality rate have decreased by 50-70% with simple population-based screening.

Yet on a global scale, 85% of annual deaths from Cervical cancer occur in low-to-middle income countries where access to preventative measures is often limited and the disease is not identified until symptoms appear in advanced stages.

Studies have indicated that visual inspection with acetic acid (VIA) screening – in the presence of good training and sustained quality assurance – can immediately detect Cervical cancer. VIA tests are helpful, particularly in countries with large low-to-medium income populations.

According to the SEER (Surveillance, Epidemiology, and End Results) database that analyzed U.S. cervical cancer diagnoses between 2010-2016, the survivability rate of “distant” advanced Cervical cancer (spread to nearby organs or distant parts of the body such as the lungs or bones) is 17%, whereas survivability of localized (early stage) disease is 92%, according to the American Cancer Society.

VIA TESTS RAPIDLY DETECT CERVICAL CANCER

Every day counts for patients and practitioners when identifying Cervical cancer, especially those with advanced cases. For years, the go-to Cervical cancer cytology-based screening test was the Pap smear (first discovered in 1923). However, after a healthcare provider collects a sample for laboratory analysis with this test, it can take weeks for an anxious woman to receive the results.

A timesaving alternative, proven in a clinical study, visual inspection with acetic acid (VIA), surpasses the effectiveness of the traditional Pap test. VIA is also used to validate other test results as a viable second opinion.

Of all the Cervical cancer screening tests used today, only visual inspection with acetic acid (VIA) provides immediate, actionable results.

Dalrada Health’s cerVIA™ cervical cancer screening test plays a vital role in immediate detection.


cerVIA TEST KIT™ BY DALRADA HEALTH

Dalrada Health believes that every life is precious.

Committed to reducing the burden of Cervical cancer worldwide, Dalrada Health dedicates support to research programs that help save lives, especially in high-risk countries like India. Long-term studies have been conducted around the world that ultimately show the effectiveness of the VIA-based screening approach. In India, for example, Cervical cancer mortality was reduced by 31% over 15 years among women screened with VIA.

Dalrada Health’s cerVIA™ screening kits ensure quality control for consistent validation processes. The single-use disposable cerVIA Test Kit™ is based on the World Health Organization’s recommended procedure for conducting a visual inspection with acetic acid (VIA). It contains all the necessary elements required for the test to be done by a healthcare professional in a primary healthcare setting.

The cerVIA Test Kit™ kit makes it easy for screening centers to manage multiple aspects such as ensuring consistency and quality of the kit’s components to confirming that all active ingredients are sourced from FDA or ISO-approved facilities. Ensuring that the validation process is consistent, each kit uses identical components. For additional information about Dalrada Health and the cerVIA Test Kit™, please visit  www.dalradahealth.com.

basic via kit
divider

DALRADA
LATEST NEWS

Skip to content